MEDICAL TECHNOLOGY
Untitled Page
Masimo's hemoglobin monitor continued ...
"Masimo SpHb is an impressive new tool that helps us to more safely
guide patients in surgery through to recovery, says Ronald Miller,
M.D., chief of Anesthesia and chairman of the Anesthesia and
Perioperative Care at UC San Francisco. “With it, not only can we spot
hemoglobin changes as they occur, but we can see where they are
heading. This ability to identify an upward or downward hemoglobin
trend on a second-by-second basis as it occurs has been of tremendous
value."
"SpHb's success during the limited market release phase
at hospitals around the world illustrates its expected significant
impact on clinical practice and patient care,” says Joe Kiani, Founder
and CEO of Masimo. “As we expected, our limited market release program
provided us with the opportunity to enhance the robustness in low
perfusion situations and broaden the cross section of individuals on
which the technology performs …”
SpHb has received regulatory
clearance in the U.S., Canada, Europe and Australia, and is now
available for sale in most of the countries in the world.
PAGE ONE
Related headlines
“OC METRO Minute,” March 24: DaVinci Biosciences – adult stem cell trial/spinal cord injury
Irvine’s Cortex Pharmaceuticals restructures, downsizes
“OC METRO Minute,” March 13: UCI’s geriatric program receives funding from Donald W. Reynolds Foundation
Studies show Irvine’s Cortex therapy slows memory loss
Irvine’s Spectrum Pharmaceuticals acquires RIT Oncology
San Clemente's STEMTech to Obama: What about adult stem cells?
Masimo's hemoglobin monitor continued ...
"Masimo SpHb is an impressive new tool that helps us to more safely
guide patients in surgery through to recovery, says Ronald Miller,
M.D., chief of Anesthesia and chairman of the Anesthesia and
Perioperative Care at UC San Francisco. “With it, not only can we spot
hemoglobin changes as they occur, but we can see where they are
heading. This ability to identify an upward or downward hemoglobin
trend on a second-by-second basis as it occurs has been of tremendous
value.""SpHb's success during the limited market release phase at hospitals around the world illustrates its expected significant impact on clinical practice and patient care,” says Joe Kiani, Founder and CEO of Masimo. “As we expected, our limited market release program provided us with the opportunity to enhance the robustness in low perfusion situations and broaden the cross section of individuals on which the technology performs …”
SpHb has received regulatory clearance in the U.S., Canada, Europe and Australia, and is now available for sale in most of the countries in the world.
PAGE ONE
Related headlines
“OC METRO Minute,” March 24: DaVinci Biosciences – adult stem cell trial/spinal cord injury
Irvine’s Cortex Pharmaceuticals restructures, downsizes
“OC METRO Minute,” March 13: UCI’s geriatric program receives funding from Donald W. Reynolds Foundation
Studies show Irvine’s Cortex therapy slows memory loss
Irvine’s Spectrum Pharmaceuticals acquires RIT Oncology
San Clemente's STEMTech to Obama: What about adult stem cells?
